

Research in Real-Life

The burden of rhinitis in Australia

Protocol for MEDA Pharmaceuticals

The burden of rhinitis in Australia

Study 1: Rhinitis treatment patterns in Australia



1 CONTENTS

1	CONTENTS	2
2	BACKGROUND	3
3	STUDY AIM & RESEARCH QUESTIONS	4
4	DATABASE	5
5	STUDY DESIGN	6
6	STUDY POPULATION	7
7	OUTCOMES	7
8	STATISTICS	8
9	RESEARCH TEAM	10
10	INTERNATIONAL STEERING COMMITTEE MEMBERS	10
11	TIMELINES	11
12	APPENDIX : RHINITIS DRUG CATEGORIES	12

STUDY SPONSOR: MEDA Pharmaceuticals Ltd, Australia

RESEARCH ORGANISATION: Research in Real-Life,

5a Coles Lane, Oakington, Cambridge, CB24 3BA.

16 Raffles Quay, #33-03 Hong Leong Building, Singapore, 048581

RESEARCH IN REAL LIFE LTD. 16 RAFFLES QUAY #33-03 HONG LEONG BUILDINGSINGAPORE 048581

 PHONE
 (+44) 01223 967 855

 FAX
 (+44) 0808 2800 792



2 BACKGROUND

Allergic rhinitis is a chronic respiratory disease with a major impact on quality of life. In a study looking at the burden of rhinitis amongst UK patients, 75% reported some impact of their rhinitis symptoms on health-related quality of life¹. Rhinitis currently affects 10-30% of the world's population², with prevalence and impact continuing to increase. In Australia, the prevalence is estimated at 19% of the population³. In addition, asthma and rhinitis often co-exist,⁴ and it has been proposed that respiratory diseases including rhinitis account for 8% of total healthcare costs in Australia⁵. Therefore Australia suffers substantial economic costs from both prescription medication for rhinitis and time taken off work by both patients and carers as a result of the disease⁶. In view of this, there may be a need for improved therapy or management of rhinitis to facilitate improved quality of life for patients and reduced economic costs for the country.

Seasonal rhinitis, intermittent rhinitis or hay fever, is caused by an inflammatory response to seasonal airborne allergens, such as grass or tree pollen⁷. Perennial rhinitis occurs in some patients who suffer from rhinitis symptoms outside the pollen season, possibly with a seasonal flare⁸. In Australia, the onset and duration of the pollen season varies in different regions of the country depending on local climate, winds and flora. The principal allergenic grasses in the subtropical area (Northern territory and Queensland) tend to pollinate from January to March. In the southern part of Australia temperate grasses flower from October to December⁹. Therefore for the purpose of this study the following areas will be studied separately: Queensland & Northern Territory (NT); Victoria, South Australia (SA), Tasmania; New South Wales (NSW) & Australian Capital Territory (ACT); Western Australia (WA).

Physicians recognise that rhinitis can be very challenging to treat¹⁰. The Allergic rhinitis and its Impact on Asthma (ARIA) guidelines¹¹ classify rhinitis as either intermittent (symptoms <4 days per week or <4 consecutive weeks) or persistent (symptoms >4 days per week and >4 consecutive weeks), and both types can be either mild, or moderate-severe depending on the effect of symptoms on the patient's life. For mild-intermittent allergic rhinitis, an H1-antihistamine (either oral or nasal) along with a short-term decongestant or Leukotriene Receptor Antagonist (LTRA) (if concomitant asthma) is recommended. For moderate-severe intermittent or mild-persistent rhinitis, intranasal corticosteroids with or without the added H1-antihistamine or LTRA are suggested, with step-up treatment recommended in persistent patients if symptoms are not managed within 2-4 weeks¹⁰. For persistent patients with moderate-severe rhinitis, intranasal corticosteroids are preferred over antihistamine or LTRA treatment¹⁰. Step-up options include increasing the corticosteroid dose and adding antihistamine for itch or sneeze, ipratropium for rhinorrhoea and a decongestant or short-term oral corticosteroid for congestion. In addition, whilst oral and nasal therapy can improve allergic conjunctivitis, some patients may require additional topical ocular therapy.

The use of multiple therapies to manage rhinitis symptoms is extremely frequent, as illustrated by a recent study in the UK¹² that demonstrated physicians frequently prescribe more than one medication to their patients. This co-prescribing behaviour becomes more frequent as the hay fever season (March-June in the UK) advances, bringing dissatisfied patients with uncontrolled symptoms



back to their physician. This suggests that initial antihistamine or intra-nasal corticosteroid monotherapy provides insufficient symptom control for many rhinitis patients.

Data from the above UK study did not include OTC medication, suggesting that the use of multiple therapies might be even more widespread as patients may purchase additional medications on top of their prescription drugs. Indeed, a 2002 survey of allergy sufferers in Australia suggests that nearly two-thirds of respondents did not consult their doctor about their current rhinitis treatment¹³. Therefore it is important to carry out further investigations that include OTC medications in order to better understand the real-life treatment of rhinitis in Australia. The proposed study will evaluate the unmet clinical need in rhinitis by examining the use of multiple therapies to control rhinitis symptoms, and the proportion of prescription and OTC medications.

3 STUDY AIM & RESEARCH QUESTIONS

Primary aim: rhinitis treatment patterns in Australia (split by geographic areaⁱ)

- 1) To assess the number of therapies (single vs. multiple drugs) used to treat rhinitis in Australia
- 2) To describe the combination of therapies used to treat rhinitis in Australia
- 3) To investigate the influence of OTC medications on the count and combination of therapies used to treat rhinitis in Australia

Secondary aims

- 4) To investigate the seasonality of rhinitis treatment patterns
- 5) To estimate the cost of rhinitis treatment in Australia

6) To investigate the relationship between rhinitis treatment patterns and co-morbid asthma treatment

ⁱ Queensland & NT; Victoria, SA, Tasmania; NSW & ACT; WA



4 DATABASE

Data source: NostraData

This study will be completed using data from NostraData, Australia. NostraData collects data on pharmacy purchases throughout Australia from 2011 to present. The data include:

A) Doctor prescription data: These data are available for about 50% of pharmacies in the country, providing excellent geographic coverage of the territory. The information is available when a patient purchases a drug with a doctor prescription. Data include date of prescription, date of purchase, drug purchased, price, instructions on the label and postcode of the purchase. Demographic data are available for 10% of patients only, as pharmacies have to add it themselves and not all pharmacies do; however, the same patients can be tracked when purchasing at different pharmacies. There is no information on patient diagnosis, however PBS codes will be provided where available

B) Point of sale data: These data include linked doctor prescription of OTC purchases and are available for about 20% of the pharmacies in the country. The data include information on the "basket" of a pharmacy customer, so can include both prescription drugs and OTC drugs. For instance, it is possible to find data relating to a specific prescription drug (e.g.: Antihistamines) and see what else was in the "basket" of the pharmacy customers who purchased that prescription drug. However, there is no other information (e.g. demographics) attached to these data, and it is not possible to track the same patients purchasing at different pharmacies or on different occasions using this dataset. Geographic coverage needs to be confirmed but we anticipate will be fairly representative of the territory.

Drug categories

Drug lists using UK drug codes have been developed by the research team, including advice from clinical specialists. These have been developed and refined over the last five years, through the RiRL's own research and in collaboration with other academic partners, in a large number of primary care database studies. A list of the rhinitis drugs that will be included in the study can be found in the appendix.



5 STUDY DESIGN

The study is a retrospective database study of pharmacy-related claims between 1st January 2013 – 31st December 2014 using data from NostraData (<u>www.nostradata.com.au</u>). Annual treatment patterns of patients with rhinitis will be documented separately for each 12-month period in each geographic areaⁱⁱ.



¹Rhinitis therapy = Antihistamines, Nasal steroids, Non-steroidal nasal spray, Leukotriene receptor antagonist, Eye drops

Figure 1. Study design

<u>Note</u>. For patients prescribed antihistamines alone, only 60% are likely to have a diagnosis of rhinitis^{III}

^{II} Queensland & NT; Victoria, SA, Tasmania; NSW & ACT; WA

^{III} Smith et. al. (2015), submitted to REG online



6 STUDY POPULATION

The study will include two datasets. Dataset A will include doctor prescription data, and dataset B will include "point of sale" data (see section 4 for details). The patient criteria for each dataset will be as follows:

6.1 DATASET A: DOCTOR PRESCRIPTION DATA

Inclusion criteria

- Purchased prescription rhinitis therapy^{iv}
- Data available for at least one continuous year of the study period (1st January 2013 31st December 2013 or 1st January 2014 – 31st December 2014)

Exclusion criteria

- Patients were prescribed oral steroids for ≥ six months during the study period (as long term oral steroids may blunt rhinitis symptoms)
- Patients were prescribed LTRA ALONE for ≥ six months during the study period (as LTRA alone is likely to have been prescribed/purchased for the treatment of asthma rather than rhinitis)

6.2 DATASET B: POINT OF SALE DATA

Inclusion criterion

Purchased OTC rhinitis therapy ^{iv} (with or without additional prescription rhinitis therapy ^{iv})

7 OUTCOMES

All analyses will be conducted separately for each study year (1st January 2013 – 31st December 2013 or 1st January 2014 – 31st December 2014) in each geographic area.

A subgroup analysis of demographic variables will be conducted in patients from Dataset A (doctor prescription data) that have demographic data available (approximately 10% of the population of Dataset A). This analysis will aim to characterise patients according to basic demographic information (gender, age).

^{iv} Rhinitis therapy : Antihistamines, Nasal steroids, Non-steroidal nasal spray, Leukotriene receptor antagonist, Eye drops



7.1 PRIMARY OUTCOMES: RHINITIS TREATMENT PATTERNS

The following outcomes will be analysed separately for Dataset A and Dataset B for each calendar year (2013 and 2014) in each geographic area

- 1. Count of therapies: To assess the frequency of single vs. multiple therapies use
- 2. **Combination of therapies**: For multiple therapy patients, to describe the combinations of different drugs used

For patients in Dataset B ("point of sale" data), with purchased OTC AND prescription rhinitis therapy only:

3. Proportion of prescribed and OTC medications

7.2 SECONDARY OUTCOMES

The following outcomes will be analysed separately for Dataset A and Dataset B for each calendar year (2013 and 2014) in each geographic area. Secondary outcomes will be analysed in relation to the primary outcomes rhinitis treatment patterns (i.e. count of therapies, combination of therapies and where appropriate proportion of prescribed and OTC medications)

4. To assess the **seasonality of rhinitis treatment patterns**. If possible treatment patterns will be documented for a subgroup of perennial patients^v (Dataset A only)

5. To estimate the **cost of rhinitis treatment** in Australia

6. To investigate the relationship between rhinitis treatment patterns and **co-morbid asthma treatment**

8 STATISTICS

- Statistical analyses will be undertaken using SPSS version 22 and R¹⁴
- Count of therapies will be reported as means and standard deviation [SD], and/or median and inter-quartile range (25th and 75th percentiles) along with minimum and maximum values. Moreover, count of therapies will be presented as single, multiple and total number of therapies.

^v Perennial patients will be defined as those who purchased rhinitis therapy outside the pollen season in their geographic area



- Within the multiple therapy patients group, the combination of different drug will be reported as absolute numbers as well as proportions and percentages.
- Prescribed and over-the-counter medications will be reported as absolute numbers as well as proportions and percentages.
- Time series analysis will be used to explore seasonality of rhinitis treatment patterns over the study period
- The cost of rhinitis treatment will be reported as mean and median purchase (in Austrian dollars) along with their inter-quartile range and minimum and maximum values of purchases. This will be reported by different groups (single therapies, multiple therapies, geographical areas, prescribed and over-the-counter medications)
- Poisson regression analyses will be used to investigate a) the relationship between rhinitis treatment patterns and co-morbid asthma treatment and b) the relationship between rhinitis treatment patterns and demographic characteristics for patients with prescribed medications (Dataset A).



9 RESEARCH TEAM

Chief Investigator

David Price: Centre of Academic Primary Care, University of Aberdeen

Research in Real LifeResearch Lead: Emily DavisResearcher: Alice DurieuxSenior Statistician: Annie BurdenStatistics Team: Vicky Thomas and Vasilis NikolaouData Team: Derek Skinner, Mark Harris and Jeremy BrockmanProject Support: Victoria CarterCommercial and Compliance Director: Catherine HuttonPerformance Director: Giano Terzic

10 INTERNATIONAL STEERING COMMITTEE MEMBERS

David Price: Centre of Academic Primary Care, University of Aberdeen

Email: respiratoryresearch@gmail.com

Pete Smith: Professor of Clinical Medicine at Griffith University

Email: pksm@mac.com

Simon Carney: Professor of Otolaryngology, Finders University

Email: simoncarney@me.com

Richard Harvey: Clinical Associate Professor, Macquarie University

Email: richard@sydneyentclinic.com

Peter Hellings: Professor of Rhinology, University of Leuven, Belgium

Email: Peter.Hellings@med.kuleuven.be

Ms Louise Christian: Senior Analyst, Nostradata

Email: lc@nostradata.com.au



11 TIMELINES

Action	Timeline			
Test data	31 st January 2015			
Feedback from RiRL	7 th February 2015			
Data extraction	14 th February 2015			
Initial analysis	22 nd April 2015			
Abstract 1 for submission as a late breaker	30 th April 2015			
Final Study report and slide set	31 st May 2015			
Manuscript	31 st August 2015			



12 APPENDIX : RHINITIS DRUG CATEGORIES

Antihistamine	Nasal steroid	Nasal spray	Eye drops	LTRA
Acrivastine	Beclomethasone	Azelastine	Nedocromil	Montelukast
Cetirizine	Betamethasone sodium	Ipratropium bromide	Lodoximide	Zafirlukast
Desloratadine	Budesonide	Oxymetazoline	Olopatadineatadin	
Fexofenadine	Ciclesonide	Chromolyn	Sodium	
Levocetrizine	Flunisolide	Antimuscarinic		
Loratadine	Flucticasone propionate	Ephedrine		
Mizolastine	Fluticasone furoate	Xylometazoline		
Alimemazine tartrate	Mometasone furoate	Sodium Cromoglycate		
Chlorphenamine	Triamcinolone acetonide	Oxymetazoline		
Cyproheptadine		Levocabastine		
Hydroxyzine				
Promethazine				



References

¹ Cauwenberge P, Van Hoecke H, Kardos P, Price D, Waserman S. The current burden of allergic AR amongst primary care practitioners and its impact on patient management. Prim Care Respir J. 2009 Mar;18(1):27-33.

² World Allergy Organisation, White Book on Allergy, 2011

³ Walls et al (2005) Optimising the management of allergic AR: an Australian perspective. Med J Aust 182:28-33.

⁴ Bousquet et al (2008) Allergic AR and its Impact on Asthma (ARIA)

⁵ Australian Institute of Health and Welfare. Health expenditure Australia 2001–02. Health and Welfare Expenditure Series no. 17. Canberra: AIHW; 2003

⁶ Eli O. Meltzer, Don A. Bukstein, The economic impact of allergic AR and current guidelines for treatment, 2011 Annals of Allergy, Asthma and Immunology:106(2)S12-S16

⁷ Ciprandi G, Cirillo I. Monosensitization and polysensitization in allergic AR. Eur J

Intern Med 2011;22:e75-e79.

⁸ Esteitie et.al. (2010) Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic AR. Ann Allergy Asthma Immunol 2010;105:155-61

⁹ Australian Society of Clinical Immunology and Allergy, <u>http://www.allergy.org.au/patients/allergic-AR-hay-fever-and-</u>sinusitis/pollen-allergy

¹⁰ Bousquet et al (2008) Allergic AR and its Impact on Asthma (ARIA)

¹¹ Management of allergic AR and its impact on asthma: Based on 2007 ARIA workshop report and IPAG handbook: in collaboration with WHO, GA2LEN, AllerGen and Wonca

¹² Price, D et al. 2014, EAACI

¹³ ABS National Health Survey, 2007–08

¹⁴ R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/